Diaceutics, the Irish data insights and solutions company, has today announced a five-year multi-million-euro partnership with US-based BioReference Laboratories. 

The exclusive partnership will see Diaceutics acquire real-time testing data from BioReference, allowing it to help pharmaceutical companies achieve faster rollouts of new drugs through better understanding of the US diagnostics market.
 
Through its partnership with BioReference, which works with 30,000 healthcare providers across the US, Diaceutics will have access to data from 50,000 patient samples per day. 

Coupled with insights from BioReference, the real-time data will help improve patient testing by ensuring that pharmaceutical companies better understand the testing patterns of physicians considering precision medicine therapies for patients.
 
Currently, Diaceutics estimates that pharmaceutical companies are missing out on more than 20% of cancer patients every year in the US due to the challenging diagnostic landscape. With 70% of new drugs in the next five years expected to be test-dependent, Diaceutics expects that percentage will increase.
 
Commenting on the deal, Executive Vice President at BioReference, Richard Faherty said, "Diaceutics is transforming patient testing and has built trusted relationships with pharmaceutical companies by providing years of expert analysis to support drug launches. We are delighted to be able to work closely with them to meet the needs of our mutual customers and patients around the world seeking more effective therapies."

Source: www.businessworld.ie